Carvedilol

Generic Name: Carvedilol

Brand Names: Coreg

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₂₆N_₂O_₄

CAS Number: 72956-09-3

Unique Ingredient Identifier: 0K47UL67F2

Background: Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker. It is currently used to treat heart failure, left ventricular dysfunction, and hypertension. The dual action of carvedilol is advantageous in combination therapies as moderate doses of 2 drugs have a decreased incidence of adverse effects compared to high dose monotherapy in the treatment of moderate hypertension.

Carvedilol was granted FDA approval on 14 September 1995.

Indication: Carvedilol is indicated to treat mild to severe heart failure, left ventricular dysfunction after myocardial infarction with ventricular ejection fraction ≤40%, or hypertension.

Associated Conditions: Atrial Fibrillation, Chronic Stable Angina Pectoris, Hypertension, LVEF ≤40% Left ventricular dysfunction, NYHA Class I or II heart failure, Chronic heart failure with reduced ejection fraction (NYHA Class III), Chronic heart failure with reduced ejection fraction (NYHA Class IV)

Associated Therapies: -

Clinical Trials

Mechanisms of Refractory Hypertension (Carvedilol)

Not Applicable

Withdrawn

Conditions: Hypertensive

Interventions: Drug: Carvedilol
Drug: Chlorthalidone

First Posted Date: 2015-02-06

Last Posted Date: 2020-06-12

Lead Sponsor: University of Alabama at Birmingham

Registration Number: NCT02357004

Therapeutic Approach to Diastolic Dysfunction in Chronic Liver Disease Patients and Its Impact on Morbidity and Mortality

Not Applicable

Completed

Conditions: Chronic Liver Disease
Diastolic Dysfunction

Interventions: Procedure: Endoscopic Variceal Ligation
Drug: Carvedilol
Drug: Ivabradine

First Posted Date: 2014-11-19

Last Posted Date: 2018-02-08

Lead Sponsor: Institute of Liver and Biliary Sciences, India

Target Recruit Count: 189

Registration Number: NCT02294292

Locations: 🇮🇳
Institute of Liver & Biliary Sciences, New Delhi, Delhi, India

Cytochrome P450 2D6 Genotype on the Clinical Effect of Carvedilol

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Carvedilol
Other: Isoproterenol Sensitivity Test

First Posted Date: 2014-11-10

Last Posted Date: 2015-06-04

Lead Sponsor: Seoul National University Hospital

Target Recruit Count: 24

Registration Number: NCT02286934

Locations: 🇰🇷
Seoul National University Bundang Hospital, Seongnam, Gyounggi, Korea, Republic of

Rate Control in Atrial Fibrillation

Phase 4

Conditions: Atrial Fibrillation

Interventions: Drug: Carvedilol
Drug: Metoprolol tartrate

First Posted Date: 2014-09-29

Last Posted Date: 2016-06-16

Lead Sponsor: Creighton University

Target Recruit Count: 20

Registration Number: NCT02251509

Locations: 🇺🇸
Creighton University, Omaha, Nebraska, United States

Biomarker Guided Therapies in Stage A/B Heart Failure

Phase 2

Completed

Conditions: Diabetes
Cardiovascular Disease
Hypertension

Interventions: Drug: Spironolactone
Other: Usual care
Drug: Carvedilol

First Posted Date: 2014-09-03

Last Posted Date: 2022-10-21

Lead Sponsor: VA Office of Research and Development

Target Recruit Count: 58

Registration Number: NCT02230891

Locations: 🇺🇸
Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas, United States

Carvedilol for the Prevention of Anthracycline/Anti-HER2 Therapy Associated Cardiotoxicity Among Women With HER2-Positive Breast Cancer Using Myocardial Strain Imaging for Early Risk Stratification

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Other: placebo
Drug: Carvedilol

First Posted Date: 2014-06-27

Last Posted Date: 2022-07-12

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 82

Registration Number: NCT02177175

Locations: 🇺🇸
Memorial Sloan Kettering West Harrison, Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

The Cardiac Insufficiency BIsoprolol Study in Japanese Patients With Chronic Heart Failure (CIBIS-J)

Not Applicable

Conditions: Chronic Heart Failure

Interventions: Drug: Bisoprolol
Drug: Carvedilol

First Posted Date: 2014-05-14

Last Posted Date: 2014-05-14

Lead Sponsor: Mebix Inc

Target Recruit Count: 220

Registration Number: NCT02137733

Locations: 🇯🇵
Chukyo Hospital, Nagoya, Aichi, Japan
🇯🇵
Takezawa Clinic, Nagoya, Aichi, Japan
🇯🇵
St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan

and more 107 locations